> For Research Purposes Only. AOD-9604 is an investigational peptide fragment of human growth hormone. It failed to meet its primary endpoint in clinical obesity development, is not approved by the FDA or EMA as a drug for any indication, and is prohibited in sport under the WADA S2 category. This article summarizes published scientific literature for educational and research purposes only. Not for human use.
Overview
AOD-9604 is a synthetic peptide corresponding to the C-terminal region of human growth hormone (hGH), specifically the fragment spanning residues 177–191 with an added N-terminal tyrosine. It was developed at Monash University and taken forward by Metabolic Pharmaceuticals Ltd (Australia) under the hypothesis that the fat-metabolizing activity of growth hormone could be separated from its growth-promoting and glucose-antagonizing activity.
That hypothesis is the whole point of the molecule, and it is what makes AOD-9604 scientifically interesting independent of whether it worked. Growth hormone reduces adipose mass, but it also raises IGF-1, promotes tissue growth, and impairs insulin sensitivity — a profile unsuitable for chronic obesity treatment. If the lipolytic domain sits in a discrete part of the molecule, a fragment containing only that domain should reduce fat without the metabolic liabilities of the whole hormone. AOD-9604 was the clinical test of that idea.
The outcome of that test is the central fact of this profile: AOD-9604 advanced through Phase I and Phase II human studies, was reported to be well tolerated, and did not demonstrate clinically meaningful weight loss versus placebo at the endpoints assessed. Development for obesity was discontinued. The compound subsequently reappeared in a different research context — intra-articular and musculoskeletal applications — and in an entirely non-scientific context as a widely marketed "research peptide."
Mechanism of Action
The mechanistic foundation predates AOD-9604 itself. Work in the early 1990s established that a synthetic peptide corresponding to the hGH C-terminal sequence 177–191 exerted antilipogenic activity independent of the intact hormone (PMID: 8358331), and a companion study examined the same fragment's effect on glucose transport in isolated rat adipocytes. These experiments defined the "lipolytic domain" concept that AOD-9604 was engineered around.
The proposed mechanism has two components. First, the fragment is reported to stimulate lipolysis in adipose tissue — increasing the breakdown of stored triglyceride — and to inhibit lipogenesis, reducing new fat deposition. Second, and critically for the design rationale, it is reported to do so without binding the growth hormone receptor in a manner that raises IGF-1, and without the insulin-antagonizing effect that characterizes intact hGH. A metabolic characterization of the synthetic lipolytic domain published in Hormone Research set out this separation-of-function profile (PMID: 11146367).
The receptor question is where the mechanism becomes less clean. Early work suggested involvement of β3-adrenergic signaling in adipocytes. A study in Endocrinology addressed this directly by comparing the effects of hGH and AOD9604 in obese mice and in β3-adrenergic receptor knockout mice, testing whether β3-AR was required for the fragment's activity (PMID: 11713213). No specific, high-affinity receptor for AOD-9604 has been definitively identified and independently confirmed. This matters: a compound with well-described phenotypic effects in rodents but no established receptor is difficult to develop rationally, and it complicates any inference from animal to human dosing.
Research Evidence
The rodent evidence is the strongest part of the dataset. A 2001 study in the International Journal of Obesity reported increased fat oxidation and reduced body weight gain in obese mice treated with the modified hGH C-terminal fragment, with the effect reported as independent of the classical GH growth axis (PMID: 11673763). The parallel Endocrinology work extended this to comparative testing against intact hGH and to receptor-knockout animals (PMID: 11713213). Together these established a reproducible rodent phenotype: reduced adiposity without the IGF-1 elevation seen with growth hormone.
Contemporary reviews of the obesity drug pipeline in the 2000s listed AOD-9604 among compounds in clinical development. A dedicated profile appeared in Current Opinion in Investigational Drugs (PMID: 15134286), and the compound was included in broader surveys of anti-obesity agents in development (PMID: 17971763) and of emerging therapies for cardiovascular risk in overweight patients with metabolic risk factors (PMID: 16931496). These reviews are useful as a record of where the compound sat in the development landscape; they are not independent efficacy evidence.
The translation gap between rodent and human results is the defining feature of this literature. The rodent effect was consistent. The human effect was not sufficient to support continued development. That pattern — robust adipose-tissue pharmacology in mice, insufficient clinical signal in humans — is common in obesity drug development and is the most honest single-sentence summary of AOD-9604.
Preclinical & Clinical Studies
Preclinical. Beyond the metabolic work, AOD-9604 was subsequently evaluated in a musculoskeletal context. A study in Annals of Clinical and Laboratory Science examined intra-articular injection of AOD9604, with or without hyaluronic acid, in a rabbit osteoarthritis model (PMID: 26275694). This represents a distinct line of investigation from the obesity program and should not be conflated with it; a cartilage-protective effect in a rabbit joint model says nothing about systemic fat metabolism in humans, and vice versa.
Clinical. Metabolic Pharmaceuticals conducted Phase I and Phase II studies in overweight and obese human subjects during the 2000s. The publicly reported profile from that program was that the compound was well tolerated across the dose range tested, did not produce the IGF-1 elevation associated with growth hormone, and did not adversely affect glucose tolerance — consistent with the separation-of-function design goal. What it also did not produce was clinically meaningful weight reduction relative to placebo, and the obesity development program was discontinued.
Researchers should note that a substantial portion of the human data from this program exists in company communications and conference material rather than in fully indexed peer-reviewed primary publications, which limits independent scrutiny of the trial design and analysis. Claims about AOD-9604's human efficacy that circulate outside the scientific literature routinely cite the safety findings — which were reasonably favorable — as though they were efficacy findings, which they were not.
The compound has more recently been discussed in reviews of peptide use in sports and musculoskeletal medicine. A 2026 review in Sports Medicine on the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance addresses this class directly (PMID: 41966639).
Safety Profile
The human safety signal from the Metabolic Pharmaceuticals program was, within the limits of the study sizes and durations, unremarkable: no IGF-1 elevation, no reported impairment of glucose tolerance, no dose-limiting toxicity identified at the doses studied. This is a meaningful result — it supports the pharmacological premise that the fragment does not behave like intact growth hormone — but it is a Phase I/II safety signal in a limited population over a limited duration, not a chronic-exposure safety profile.
Several caveats apply to any research use:
- •No long-term data. There is no published multi-year human exposure dataset. The clinical program was terminated for efficacy, not extended for safety characterization.
- •Anti-doping status. AOD-9604 is prohibited in sport under the World Anti-Doping Agency's S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) category. Analytical methods for its detection in urine and blood have been developed and published (PMID: 25382550; PMID: 26578461; PMID: 26213263). Athletes subject to testing should treat this as a certain adverse-analytical-finding risk, not a gray area.
- •Regulatory status. AOD-9604 is not an FDA-approved drug. It has been the subject of regulatory attention regarding its marketing as a dietary ingredient; it does not meet the criteria for that classification.
- •Unregulated supply. Material sold through research-chemical channels is not subject to verified identity, purity, or sterility testing.
Research Context
AOD-9604 is a well-documented example of a rational drug-design hypothesis that was properly tested and did not survive the test. The separation-of-function premise — isolate the lipolytic domain, discard the growth and glucose effects — was sound, the preclinical work supported it, and the human trials showed that the retained activity was not large enough to matter clinically at the doses and durations studied.
Its continuing presence in the research-peptide market is therefore a case study in how compounds persist commercially after failing scientifically. The marketing narrative typically relies on the preclinical lipolysis data and the favorable Phase I safety findings while omitting the Phase II efficacy outcome that ended the program.
The more scientifically live question today is the musculoskeletal one. The rabbit osteoarthritis work (PMID: 26275694) suggests a distinct mechanism of interest in cartilage, and this line has not been adequately explored in controlled human studies. Any future clinical program in that indication would need to start from first principles rather than borrowing credibility from the obesity data.
Disclaimer
For Research Purposes Only. This article is an educational summary of published scientific literature. AOD-9604 is not approved by the FDA, EMA, or any comparable regulatory agency for the diagnosis, treatment, cure, or prevention of any disease, and it is not approved for human consumption or as a dietary supplement ingredient. It is prohibited in sport under WADA regulations. Nothing here is medical advice, a treatment recommendation, or a dosing protocol. Peptides.SO does not sell peptides and does not endorse the use of any research compound in humans. Individuals with health concerns should consult a licensed physician. Researchers should ensure all work complies with applicable institutional, national, and international regulations.